Finance

Lists
ZTS:NYSE
Zoetis Inc
၇၅.၆၅ US$
+၁.၁၁%
(+၀.၈၃) 1D
၇၆.၀၀ US$
+၀.၄၆% (+၀.၃၅)
Pre-market
Closed: အောက် ၁၂, GMT-၄ ၁၆:၀၂:၁၉  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
၇၅.၀၀ US$
High
၇၅.၆၉ US$
Low
၇၄.၁၇ US$
Mkt. cap
ဋေ ၃.၁၃ ထ
Avg. vol.
၄.၅၅ သန်း
Volume
၅.၇၃ ထောင်
Dividend
၂.၈၀%
Quarterly dividend
၀.၅၃ US$
Ex-dividend date
၂၀၂၆ ဇူ ၂၀
P/E ratio
၁၂.၄၄
52-wk high
၁၄၈.၃၀ US$
52-wk low
၆၈.၇၇ US$
EPS
၆.၀၈ US$
Beta
၀.၇၄
Shares outstanding
၄၁.၃၂ ကုဋေ
No. of employees
၁ သောင်း
Open
၇၅.၀၀ US$
High
၇၅.၆၉ US$
Low
၇၄.၁၇ US$
Mkt. cap
ဋေ ၃.၁၃ ထ
Avg. vol.
၄.၅၅ သန်း
Volume
၅.၇၃ ထောင်
Dividend
၂.၈၀%
Quarterly dividend
၀.၅၃ US$
Ex-dividend date
၂၀၂၆ ဇူ ၂၀
P/E ratio
၁၂.၄၄
52-wk high
၁၄၈.၃၀ US$
52-wk low
၆၈.၇၇ US$
EPS
၆.၀၈ US$
Beta
၀.၇၄
Shares outstanding
၄၁.၃၂ ကုဋေ
No. of employees
၁ သောင်း
News stories
From web sources and news partners
News Corp
News Corp
·
ပြီးခဲ့သည့် ၁၂ နာရီ
Zoetis Inc. stock outperforms competitors on strong trading day
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees၁.၄၅ သောင်း
Founded၁၉၅၂
HeadquartersParsippany-Troy Hills, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitezoetis.com
Analyst ratings
Based on 11 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
4
Hold
7
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current ၇၅.၆၅ US$
၁၁၅.၀၀ US$ (+၅၂.၀၂%)
Average
၉၀.၇၁ US$ (+၁၉.၉၁%)
Lowest
၈၀.၀၀ US$ (+၅.၇၅%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Jonathan Block
Stifel Nicolaus
Hold
Reiterated
-
-
09/18/2026
Steve Scala
TD Cowen
Buy
Reiterated
၉၄.၀၀ US$
+၂၄.၃%
08/25/2026
Glen Santangelo
Barclays
Hold
Reiterated
၈၅.၀၀ US$
+၁၂.၄%
08/17/2026
Chris Schott
J.P. Morgan
Buy
Maintained
၁၁၅.၀၀ US$
+၅၂%
08/10/2026
Daniel Grosslight
Citi
Buy
Maintained
၉၆.၀၀ US$
+၂၆.၉%
08/11/2026
David Westenberg
Piper Sandler
Hold
Maintained
၈၀.၀၀ US$
+၅.၈%
08/10/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
၈၅.၀၀ US$
+၁၂.၄%
08/10/2026
Andrea Alfonso
UBS
Hold
Reiterated
၈၀.၀၀ US$
+၅.၈%
08/07/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
၉၅.၀၀ US$
+၂၅.၆%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
05/08/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
၁၃၁.၀၀ US$
+၇၃.၂%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
၁၆၀.၀၀ US$
+၁၁၁.၅%
02/26/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
၁.၈၇ US$ / ၁.၈၅ US$
+၀.၉၅%beat
Revenue / Est. (USD)
၂၄၆.၈၀ ဋေ / ၂၅၁.၂၀ ဋေ
-၁.၇၅%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၂၄၀.၀၀ ဋေ
၂၃၈.၇၀ ဋေ
၂၂၆.၂၀ ဋေ
၂၄၆.၈၀ ဋေ
Cost of goods sold
၆၈.၂၀ ကုဋေ
၇၁.၁၀ ကုဋေ
၆၄.၀၀ ကုဋေ
၆၇.၀၀ ကုဋေ
Cost of revenue
၆၈.၂၀ ကုဋေ
၇၁.၁၀ ကုဋေ
၆၄.၀၀ ကုဋေ
၆၇.၀၀ ကုဋေ
Research and development expenses
၁၇.၀၀ ကုဋေ
၁၉.၉၀ ကုဋေ
၁၈.၀၀ ကုဋေ
၁၇.၃၀ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၅၇.၂၀ ကုဋေ
၆၁.၈၀ ကုဋေ
၅၈.၄၀ ကုဋေ
၅၈.၉၀ ကုဋေ
Operating expense
၇၇.၄၀ ကုဋေ
၈၄.၈၀ ကုဋေ
၇၉.၅၀ ကုဋေ
၇၉.၃၀ ကုဋေ
Total operating expenses
၁၄၅.၆၀ ဋေ
၁၅၅.၉၀ ဋေ
၁၄၃.၅၀ ဋေ
၁၄၆.၃၀ ဋေ
Operating income
၉၄.၄၀ ကုဋေ
၈၂.၈၀ ကုဋေ
၈၂.၇၀ ကုဋေ
၁၀၀.၅၀ ဋေ
Other non operating income
-
-၆.၀၀ သန်း
-၁.၀၀ သန်း
-၂.၀၀ သန်း
EBT including unusual items
၈၈.၇၀ ကုဋေ
၇၆.၁၀ ကုဋေ
၇၅.၈၀ ကုဋေ
၈၆.၆၀ ကုဋေ
EBT excluding unusual items
၈၉.၉၀ ကုဋေ
၇၈.၀၀ ကုဋေ
၇၇.၉၀ ကုဋေ
၉၄.၈၀ ကုဋေ
Income tax expense
၁၆.၆၀ ကုဋေ
၁၅.၈၀ ကုဋေ
၁၅.၇၀ ကုဋေ
၁၇.၅၀ ကုဋေ
Effective tax rate
၁၈.၇၁%
၂၀.၇၆%
၂၀.၇၁%
၂၀.၂၁%
Other operating expenses
-
-
-
-
Net income
၇၂.၁၀ ကုဋေ
၆၀.၃၀ ကုဋေ
၆၀.၁၀ ကုဋေ
၆၉.၁၀ ကုဋေ
Net profit margin
၃၀.၀၄%
၂၅.၂၆%
၂၆.၅၇%
၂၈.၀၀%
Earnings per share
၁.၇၀
၁.၄၈
၁.၅၃
၁.၈၇
Interest and investment income
၂.၆၀ ကုဋေ
၂.၅၀ ကုဋေ
၂.၁၀ ကုဋေ
၁.၆၀ ကုဋေ
Interest expense
-၅.၈၀ ကုဋေ
-၅.၇၀ ကုဋေ
-၆.၂၀ ကုဋေ
-၆.၁၀ ကုဋေ
Net interest expenses
-၃.၂၀ ကုဋေ
-၃.၂၀ ကုဋေ
-၄.၁၀ ကုဋေ
-၄.၅၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၁၀၆.၈၀ ဋေ
၉၀.၃၀ ကုဋေ
၉၄.၆၀ ကုဋေ
၁၁၂.၄၀ ဋေ
Gain or loss from assets sale
-
-
-၆.၀၀ သန်း
-၁.၀၀ သန်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ